Emily Feld

1.2k total citations
17 papers, 449 citations indexed

About

Emily Feld is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Emily Feld has authored 17 papers receiving a total of 449 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 5 papers in Surgery. Recurrent topics in Emily Feld's work include Cancer Immunotherapy and Biomarkers (8 papers), Bladder and Urothelial Cancer Treatments (4 papers) and Lung Cancer Treatments and Mutations (3 papers). Emily Feld is often cited by papers focused on Cancer Immunotherapy and Biomarkers (8 papers), Bladder and Urothelial Cancer Treatments (4 papers) and Lung Cancer Treatments and Mutations (3 papers). Emily Feld collaborates with scholars based in United States, Israel and United Kingdom. Emily Feld's co-authors include Leora Horn, Emily Castellanos, Tara C. Mitchell, Sharon Phillips, Fei Ye, Douglas B. Johnson, Jeffrey A. Sosman, Donald P. Lawrence, Shilin Zhao and Ryan J. Sullivan and has published in prestigious journals such as Journal of Clinical Oncology, European Urology and Journal of Thoracic Oncology.

In The Last Decade

Emily Feld

16 papers receiving 444 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Emily Feld United States 9 263 219 164 92 55 17 449
Shiven B. Patel United States 12 276 1.0× 168 0.8× 106 0.6× 41 0.4× 31 0.6× 47 420
J. Mezger Germany 10 319 1.2× 219 1.0× 264 1.6× 60 0.7× 100 1.8× 26 584
Gunta Purkalne Latvia 12 183 0.7× 119 0.5× 151 0.9× 129 1.4× 49 0.9× 31 425
Melinda Laine Hsu United States 11 214 0.8× 119 0.5× 160 1.0× 44 0.5× 23 0.4× 28 422
Rabih Said United States 11 153 0.6× 105 0.5× 118 0.7× 118 1.3× 27 0.5× 33 390
Αngeliki Andrikopoulou Greece 13 220 0.8× 89 0.4× 158 1.0× 78 0.8× 24 0.4× 41 438
Jo Raskin Belgium 10 178 0.7× 243 1.1× 114 0.7× 64 0.7× 34 0.6× 39 392
Humera Khurshid United States 11 190 0.7× 137 0.6× 70 0.4× 41 0.4× 80 1.5× 24 342
Enrica Capelletto Italy 12 238 0.9× 265 1.2× 182 1.1× 76 0.8× 22 0.4× 31 444
Enzo Veltri Italy 10 353 1.3× 150 0.7× 71 0.4× 61 0.7× 42 0.8× 13 421

Countries citing papers authored by Emily Feld

Since Specialization
Citations

This map shows the geographic impact of Emily Feld's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emily Feld with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emily Feld more than expected).

Fields of papers citing papers by Emily Feld

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Emily Feld. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emily Feld. The network helps show where Emily Feld may publish in the future.

Co-authorship network of co-authors of Emily Feld

This figure shows the co-authorship network connecting the top 25 collaborators of Emily Feld. A scholar is included among the top collaborators of Emily Feld based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Emily Feld. Emily Feld is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Das, Jeeban Paul, Thomas Powles, Dean F. Bajorin, et al.. (2024). Clinical outcomes of sacituzumab govitecan (SG) after prior exposure to enfortumab vedotin (EV) in patients with metastatic urothelial carcinoma (mUC).. Journal of Clinical Oncology. 42(16_suppl). 4581–4581. 1 indexed citations
2.
Kotecha, Ritesh R., Andrea Knežević, Joshua Chaim, et al.. (2023). A Phase 2 Trial of Talazoparib and Avelumab in Genomically Defined Metastatic Kidney Cancer. European Urology Oncology. 7(4). 804–811. 11 indexed citations
3.
Kotecha, Ritesh R., Chung‐Han Lee, Deaglan Joseph McHugh, et al.. (2022). A phase II study of talazoparib and avelumab in VHL deficient clear cell renal cell carcinoma.. Journal of Clinical Oncology. 40(6_suppl). 347–347. 1 indexed citations
4.
Yu, Shun, Anh N. Le, Emily Feld, et al.. (2021). A Natural Language Processing–Assisted Extraction System for Gleason Scores: Development and Usability Study. JMIR Cancer. 7(3). e27970–e27970. 7 indexed citations
5.
Lee, Daniel J., Ryan Hausler, Anh N. Le, et al.. (2021). Association of Inherited Mutations in DNA Repair Genes with Localized Prostate Cancer. European Urology. 81(6). 559–567. 21 indexed citations
6.
Feld, Emily, Eric K. Singhi, Sharon Phillips, et al.. (2019). Palliative Care Referrals for Advanced Non–small-cell Lung Cancer (NSCLC): Patient and Provider Attitudes and Practices. Clinical Lung Cancer. 20(3). e291–e298. 32 indexed citations
7.
Chao, Hann‐Hsiang, Emily Feld, Vivek Narayan, Ronnie Sebro, & Joshua Jones. (2019). Radiation Recall Myositis After Carboplatin/Docetaxel Chemotherapy. Practical Radiation Oncology. 10(1). e50–e52. 2 indexed citations
8.
Feld, Emily, Joanna Harton, Neal J. Meropol, et al.. (2019). Effectiveness of First-line Immune Checkpoint Blockade Versus Carboplatin-based Chemotherapy for Metastatic Urothelial Cancer. European Urology. 76(4). 524–532. 32 indexed citations
9.
Parikh, Ravi B., Emily Feld, Matthew D. Galsky, et al.. (2019). First-line immune checkpoint inhibitor use in cisplatin-eligible patients with advanced urothelial carcinoma: a secular trend analysis. Future Oncology. 16(2). 4341–4345. 10 indexed citations
10.
Parikh, Ravi B., Matt D. Galsky, Shrujal S. Baxi, et al.. (2019). Real-world trends in first-line checkpoint inhibitor use (CPI) in advanced urothelial cell carcinoma (aUC).. Journal of Clinical Oncology. 37(7_suppl). 392–392. 2 indexed citations
11.
Feld, Emily & Tara C. Mitchell. (2018). Immunotherapy in Melanoma. Immunotherapy. 10(11). 987–998. 25 indexed citations
12.
Feld, Emily & Leora Horn. (2017). Emerging role of nivolumab in the management of patients with non-small-cell lung cancer: current data and future perspectives. OncoTargets and Therapy. Volume 10. 3697–3708. 3 indexed citations
13.
Castellanos, Emily, Emily Feld, Mónica V. Estrada, et al.. (2017). Clinical Response to Anti–Programmed Death 1 After Response and Subsequent Progression on Anti–Programmed Death Ligand 1 Therapy. JCO Precision Oncology. 1(1). 1–9. 2 indexed citations
14.
Castellanos, Emily, Emily Feld, & Leora Horn. (2016). Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR -Mutated Non–Small Cell Lung Cancer. Journal of Thoracic Oncology. 12(4). 612–623. 209 indexed citations
15.
Feld, Emily, Leora Horn, & Sharon Phillips. (2016). Referral practices of medical oncologists to palliative care for patients with metastatic non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 34(26_suppl). 108–108. 4 indexed citations
16.
Johnson, Douglas B., Eirini Pectasides, Emily Feld, et al.. (2016). Sequencing Treatment in BRAF V600 Mutant Melanoma: Anti-PD-1 Before and After BRAF Inhibition. Journal of Immunotherapy. 40(1). 31–35. 75 indexed citations
17.
Feld, Emily & Leora Horn. (2016). Targeting PD-L1 for Non-Small-Cell Lung Cancer. Immunotherapy. 8(6). 747–758. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shiven B. Patel Breakdown of academic impact, for papers by J. Mezger Breakdown of academic impact, for papers by Gunta Purkalne Breakdown of academic impact, for papers by Melinda Laine Hsu Breakdown of academic impact, for papers by Rabih Said Breakdown of academic impact, for papers by Αngeliki Andrikopoulou Breakdown of academic impact, for papers by Jo Raskin Breakdown of academic impact, for papers by Humera Khurshid Breakdown of academic impact, for papers by Enrica Capelletto Breakdown of academic impact, for papers by Enzo Veltri
Rankless by CCL
2026